0.54
+1.90%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CK Life Sciences Intl (Holdings)
Its shares trade on HKEX under the ticker 775.HK. It has been listed since 16 July 2002. In the fiscal year to 31 December 2025, it reported revenue of HK$5.41bn and a net loss of HK$188.4m. At that date it held total assets of HK$11.84bn and shareholders' equity of HK$3.78bn.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. The company employs 1,829 full-time employees The company went IPO on 2002-07-16. The firm operates through three segments. The Health segment is engaged in the development, production, marketing and sales of healthcare and pharmaceutical products. The healthcare brands under the Company include Lipa, Vitaquest and Sante Naturelle, among others. Its pharmaceutical products include cancer-related pharmaceuticals and painkillers, among others. The Agriculture-related Businesses segment is engaged in the operation of vineyards, as well as the development, production, marketing and sales of agriculture and related products. Its agricultural products include fertilizers and crop protection products, among others. The Investment segment is engaged in the investment in financial and investment products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jul 2002
- Employees
- 1,829
- Website
- ck-lifesciences.com ↗
Leadership
Pay as last reported
- Mr. Tzar Kuoi LiExecutive Chairman of the Board, since 2002HK$125,000
- Mr. Hing Lam KamPresident, Executive DirectorHK$2.8m
- Mr. Lee YuenChief Executive Officer, Vice President, Executive Director, since 2024
- Mr. Ying Choi YuDeputy Chairman of the Board, Executive Director, since 2024HK$13.9m
- Mr. Yiu Leung MoChief Financial Officer, since 2020
- Mr. Angus Barrington-CaseChief Executive Officer of Regenal Investments Pty Limited, since 2020
- Mr. Patrick BrueggmanPresident, Chief Executive Officer of Vitaquest International LLC
- Mr. Mark HerronChief Executive Officer of Australian Agribusiness Holdings Pty Limited
- Mr. Andrew SpeedChief Executive Officer of the Cheetham Salt Group
- Mr. Rob TannaChief Executive Officer of Lipa Pharmaceuticals Limited
- Mr. Philippe TrudeauPresident, Chief Executive Officer of Sante Naturelle Adrien Gagnon Limited
- Mr. Tak Chuen IpSenior Vice President, Chief Investment Officer, Executive DirectorHK$1.6m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research & Development capabilities, driving innovation and new product development.
- Diversified product portfolio, offering a wide range of healthcare and life sciences products.
- Established presence in the global market, enabling international expansion opportunities.
- Strong financial performance, ensuring stability and long-term growth prospects.
Weaknesses
- Dependence on a few key markets, making the company vulnerable to economic fluctuations in those regions.
- Limited brand recognition compared to major competitors, affecting market share and customer loyalty.
- Relatively higher cost structure compared to some competitors, potentially affecting price competitiveness.
- Limited distribution network in certain geographical areas, hindering market penetration.
Opportunities
- Growing demand for healthcare and life sciences products globally, providing expansion opportunities.
- Emerging markets offer untapped potential for business growth and market diversification.
- Increasing focus on personalized medicine and biotechnology, creating demand for specialized products.
- Strategic partnerships and collaborations with research institutes and pharmaceutical companies for mutual benefits.
Threats
- Intense competition from global and local players, leading to pricing pressure and market saturation.
- Regulatory changes and compliance requirements impacting product development, manufacturing, and sales.
- Economic downturns and global financial instability affecting consumer spending and demand for healthcare products.
- Rapid technological advancements and disruptive innovations altering market dynamics and competition.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.